Denovo inks option deal for DB102 in selected clinical indications

21 January 2020
denovo_large

US biopharma firm Denovo Biopharma has entered into an exclusive option-to-license agreement with Rumpus Therapeutics for selected indications for DB102 (enzastaurin).

Under the terms of the deal, Rumpus gains the option to acquire an exclusive license to develop and commercialize DB102 worldwide for rare genetic pediatric onset or congenital disorders outside of oncology. The agreement includes an undisclosed upfront option payment, a fee to exercise the option, and pre-negotiated milestones and royalties upon exercise of the option.  Financial terms were not disclosed.

Denovo acquired enzastaurin, a late-stage oncology drug from pharma major Eli Lilly (NYSE: LLY) in 2014, gaining all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology